研究表明，PD-L1不仅作为经典的免疫检查点分子发挥作用，还可以通过抑制树突状细胞中的铁死亡，增强抗肿瘤免疫应答。 清华大学药学院唐海东 ...

According to the Company, detailed results will be presented at a medical meeting in 2025. A phase 3 trial evaluating tiragolumab in combination with Tecentriq ® (atezolizumab) in adults with PD ...

compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC). SKYSCRAPER-01 is a global Phase III, randomized, double-blinded study ...

Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to ...

as first-line therapy for PD-L1-positive, advanced non-small cell lung cancer (NSCLC) in a Chinese trial. In the phase III ...

compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC). SKYSCRAPER-01 is a global phase III, randomised, double-blind study ...